Metformin was also favored over sulfonylureas for cardiovascular mortality (low-quality evidence), as evidenced by 4 cohort studies (92, 94, 96, 101), although 1 prospective cohort study (94) showed slightly higher cardiovascular mortality rates for metformin than for sulfonylurea monotherapy. Also, ADOPT (A Diabetes Outcome Progression Trial) (89) reported only 1 fatal CHF event in patients treated with either metformin or glyburide (nonstatistically significant difference), but patients treated with glyburide generally experienced fewer CHF as well as cardiovascular events.
. Correction: Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. Ann Intern Med. 2012;156:756. doi: https://doi.org/10.7326/0003-4819-156-10-201205150-00024
Download citation file:
Published: Ann Intern Med. 2012;156(10):756.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use